Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data

References

• R Core Team. 2017. R language 3.1.2. 2017. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• Amsterdam, J. V., A. Opperhuizen, and W. Van den Brink. 2011. Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology: RTP 59 (3):423–29. doi:10.1016/j.yrtph.2011.01.006.
   PubMed Web of Science ®Google Scholar
• Bienemann, B., N. S. Ruschel, M. L. Campos, M. A. Negreiros, D. C. Mograbi, and G. Carrà. 2020. Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PloS One 15 (2):e0229067. doi:10.1371/journal.pone.0229067.
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., M. P. Bradstreet, F. S. Barrett, K. A. MacLean, R. Jesse, M. W. Johnson, and R. R. Griffiths. 2016. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology 30 (12):1268–78. doi:10.1177/0269881116662634.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Castellanos, J. P., C. Woolley, K. A. Bruno, F. Zeidan, A. Halberstadt, and T. Furnish. 2020. Chronic pain and psychedelics: A review and proposed mechanism of action. Regional Anesthesia & Pain Medicine 45 (7):486–94. doi:10.1136/rapm-2020-101273.
   PubMed Web of Science ®Google Scholar
• Daniel, J., and M. Haberman. 2017. Clinical potential of psilocybin as a treatment for mental health conditions. The Mental Health Clinician 7 (1):24–28. doi:10.9740/mhc.2017.01.024.
   PubMedGoogle Scholar
• EROWID (1995). Erowid experience vaults [Internet]. Available from: https://www.erowid.org/experiences/exp_list.shtml
   Google Scholar
• Gashi, L., S. Sandberg, and W. Pedersen. 2021. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy 87:102997. doi:10.1016/j.drugpo.2020.102997.
   PubMed Web of Science ®Google Scholar
• Gaynes, B. N., S. W. Lloyd, L. Lux, G. Gartlehner, R. A. Hansen, S. Brode, D. E. Jonas, T. S. Evans, M. Viswanathan, and K. N. Lohr. 2014. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. The Journal of Clinical Psychiatry 75 (5):29758. doi:10.4088/JCP.13r08815.
   Web of Science ®Google Scholar
• GDS. Global Drug Survey 2022 [Internet]. Available from: https://www.globaldrugsurvey.com/gds-2022/
   Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Gukasyan, N., and S. K. Narayan. 2022. Menstrual changes and reversal of Amenorrhea induced by classic psychedelics: A case series. Journal of Psychoactive Drugs 1–6. doi:10.1080/02791072.2022.2157350.
   Web of Science ®Google Scholar
• Hirschfeld, T., and T. T. Schmidt. 2021. Dose–response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology 35 (4):384–97. doi:10.1177/0269881121992676.
   PubMed Web of Science ®Google Scholar
• Hyman, S. E. 2014. Revitalizing psychiatric therapeutics. Neuropsychopharmacology 39 (1):220–29. doi:10.1038/npp.2013.181.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., R. R. Griffiths, P. S. Hendricks, and J. E. Henningfield. 2018. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143–66. doi:10.1016/j.neuropharm.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Kim, H. Y. 2017. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restorative Dentistry & Endodontics 42 (2):152–55. doi:10.5395/rde.2017.42.2.152.
   PubMedGoogle Scholar
• Kramer, I., C. J. Simons, J. T. Wigman, D. Collip, N. Jacobs, C. Derom, E. Thiery, J. van Os, I. Myin-Germeys, and M. Wichers. 2014. Time-lagged moment-to-moment interplay between negative affect and paranoia: New insights in the affective pathway to psychosis. Schizophrenia Bulletin 40 (2):278–86. doi:10.1093/schbul/sbs194.
   PubMed Web of Science ®Google Scholar
• Letheby, C., and P. Gerrans. 2017. Self unbound: Ego dissolution in psychedelic experience. Neuroscience of Consciousness 2017 (1):nix016. doi:10.1093/nc/nix016.
   PubMed Web of Science ®Google Scholar
• Loubère, L., and P. Ratinaud (2014). Documentation IRaMuTeQ 0.6 alpha 3 version 0.1. [Internet]. Available from: http://www.iramuteq.org/documentation/fichiers/documentation_19_02_2014.pdf
   Google Scholar
• Lowe, H., N. Toyang, B. Steele, H. Valentine, J. Grant, A. Ali, W. Ngwa, and L. Gordon. 2021. The therapeutic potential of psilocybin. Molecules 15;26 (10):2948. doi:10.3390/molecules26102948.
   Web of Science ®Google Scholar
• Luoma, J. B., C. Chwyl, G. J. Bathje, A. K. Davis, and R. Lancelotta. 2020. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs 52 (4):289–99. doi:10.1080/02791072.2020.1769878.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, National Health Council. (2016). Resolution No 510 of April 7 2016. Brazil
   Google Scholar
• Nour, M. M., L. Evans, D. Nutt, and R. L. Carhart-Harris. 2016. Ego-dissolution and psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience 10 (6):1–13. doi:10.3389/fnhum.2016.00269.
   PubMed Web of Science ®Google Scholar
• Olchanski, N., M. M. Myers, M. Halseth, P. L. Cyr, L. Bockstedt, T. F. Goss, and R. H. Howland. 2013. The economic burden of treatment-resistant depression. Clinical Therapeutics 35 (4):512–22. doi:10.1016/j.clinthera.2012.09.001.
   PubMed Web of Science ®Google Scholar
• Oss, O. T., and O. N. Oeric. 1993. Psilocybin: Magic mushroom grower’s guide: A handbook for psilocybin enthusiasts. 2nd ed. California: Quick American Archives.
   Google Scholar
• Preller, K. H., T. Pokorny, A. Hock, R. Kraehenmann, P. Stämpfli, E. Seifritz, M. Scheidegger, and F. X. Vollenweider. 2016. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proceedings of the National Academy of Sciences 113 (18):5119–24. doi:10.1073/pnas.1524187113.
   PubMed Web of Science ®Google Scholar
• Preller, K. H., and F. X. Vollenweider. 2016. Phenomenology, structure, and dynamic of psychedelic states. Behavioral Neurobiology of Psychedelic Drugs 36:221–56. doi:10.1007/7854_2016_459.
   Google Scholar
• Ratinaud, P., and P. Marchand. 2012. Application de la méthode ALCESTE à de “gros” corpus et stabilité des “mondes lexicaux”: analyse du “Cable-Gate” avec IRaMuTeQ. Em: Actes des 11eme Journées internationales d’Analyse statistique des Données Textuelles 835–44. Liège, Belgium. Available from. http://goo.gl/nhM1Fe
   Google Scholar
• Ross, S., G. Agin-Liebes, S. Lo, R. J. Zeifman, L. Ghazal, J. Benville, S. Franco Corso, C. Bjerre Real, J. Guss, A. Bossis, et al. 2021. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacology and Translational Science 4 (2):553–62. doi:10.1021/acsptsci.1c00020.
   PubMedGoogle Scholar
• Rucker, J. J., L. A. Jelen, S. Flynn, K. D. Frowde, and A. H. Young. 2016. Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology 30 (12):1220–29. doi:10.1177/0269881116679368.
   PubMed Web of Science ®Google Scholar
• Salvador, P. T. C. O., A. T. de Lima Gomes, C. C. F. M. Rodrigues, F. B. T. Chiavone, K. Y. A. Alves, M. dos Santos Bezerril, and V. E. P. Santos. 2018. Uso do software IRaMuTeQ nas pesquisas brasileiras da área da saúde: uma scoping review. Revista Brasileira Em Promoção Da Saúde 31. doi:10.5020/18061230.2018.8645.
   Google Scholar
• Serafini, G., R. Howland, F. Rovedi, P. Girardi, and M. Amore. 2014. The role of ketamine in treatment-resistant depression: A systematic review. Current Neuropharmacology 12 (5):444–61. doi:10.2174/1570159X12666140619204251.
   PubMed Web of Science ®Google Scholar
• Shalit, N., J. Rehm, and S. Lev-Ran. 2019. Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III. Addictive Behaviors 89:35–43. doi:10.1016/j.addbeh.2018.09.020.
   PubMed Web of Science ®Google Scholar
• Uthaug, M. V., K. Van Oorsouw, K. P. C. Kuypers, M. Van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, and J. G. Ramaekers. 2018. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology 235 (10):2979–89. doi:10.1007/s00213-018-4988-3.
   PubMed Web of Science ®Google Scholar
• van Oorsouw, K. I., M. V. Uthaug, N. L. Mason, N. J. Broers, and J. G. Ramaekers. 2021. Sub-acute and long-term effects of ayahuasca on mental health and well-being in healthy ceremony attendants: A replication study. Journal of Psychedelic Studies 5 (2):103–13. doi:10.1556/2054.2021.00174.
   Google Scholar
• Wheeler, S. W., and N. L. Dyer. 2020. A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, & Practice 7 (3):279. doi:10.1037/cns0000237.
   Google Scholar
• Yu, C. L., C. S. Liang, F. C. Yang, Y. K. Tu, C. W. Hsu, A. F. Carvalho, B. Stubbs, T. Thompson, C. K. Tsai, T. C. Yeh, et al. 2022. Trajectory of antidepressant effects after single-or two-dose administration of psilocybin: A systematic review and multivariate meta-analysis. Journal of Clinical Medicine 11 (4):938. doi:10.3390/jcm11040938.
   PubMed Web of Science ®Google Scholar